%0 Journal Article
%A Cobo Dols, Manuel
%A Beato Zambrano, Carmen
%A Cabezon-Gutierrez, Luis
%A Chicas-Sett, Rodolfo
%A Blancas Lopez-Barajas, Maria Isabel
%A Garcia Navalon, Francisco Javier
%A Firvida Perez, Jose Luis
%A Serrano Bermudez, Gala
%A Togores Torres, Pilar
%A Delgado Mingorance, Ignacio
%A Giraldo Marin, Alexandra
%A Libran Oriol, Anna
%A Paredes Lario, Alfredo
%A Sanchez Maurino, Pedro
%A Higuera Gomez, Oliver
%A Moreno Munoz, Diana
%A Huerta Gonzalez, Ibone
%A Sanz-Yague, Almudena
%A Soler Lopez, Begona
%T One-year efficacy and safety of naloxegol on symptoms and quality of life related to opioid-induced constipation in patients with cancer: KYONAL study
%D 2021
%@ 2045-435X
%U https://hdl.handle.net/10668/25895
%X Objectives Naloxegol is a peripherally acting mu-opioid receptor antagonist (PAMORA) for treatment of opioid-induced constipation (OIC). The main objective was to analyse the long-term efficacy, quality of life (QOL) and safety of naloxegol in patients with cancer in a real-world study. Methods This one-year prospective study included patients older than 18 years, with active oncological disease who were under treatment with opioids for pain control and Karnofsky >= 50 and OIC with inadequate response to treatment with laxative (s). All the patients received treatment with naloxegol according to clinical criteria. The main efficacy objectives were measured by the patient assessment of constipation QOL questionnaire (PAC-QOL), the PAC symptoms (PAC-SYM), the response rate at day 15, and months 1-3-6-12, and global QOL (EuroQoL-5D-5L). Results A total of 126 patients (58.7% males) with a mean age of 61.5 years (95% CI 59.4 to 63.7) were included. PAC-SYM and PAC-QOL total score and all their dimensions improved from baseline (p= 50 and OIC with inadequate response to treatment with laxative (s). All the patients received treatment with naloxegol according to clinical criteria. The main efficacy objectives were measured by the patient assessment of constipation QOL questionnaire (PAC-QOL), the PAC symptoms (PAC-SYM), the response rate at day 15, and months 1-3-6-12, and global QOL (EuroQoL-5D-5L). Results A total of 126 patients (58.7% males) with a mean age of 61.5 years (95% CI 59.4 to 63.7) were included. PAC-SYM and PAC-QOL total score and all their dimensions improved from baseline (p
%K constipation
%K cancer
%K pain
%K Induced bowel dysfunction
%K Pooled analysis
%K Noncancer pain
%K Prevalence
%K Pathophysiology
%K Validation
%K Management
%K Disorders
%K Severity
%~